Navigation Links
Study shows in vivo endomicroscopy improves detection of Barrett's esophagus-related neoplasia

DOWNERS GROVE, Ill. February 19, 2014 New research shows that the addition of confocal laser endomicroscopy to high-definition white-light endoscopy enables improved real-time endoscopic diagnosis of Barrett's esophagus dysplasia (neoplastic tissue) by using targeted biopsies of abnormal mucosa to reduce unnecessary mucosal biopsies and potentially reduce costs. It may also positively influence patient care by changing the plan for immediate endoscopic management. The study appears in the February issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy (ASGE).

Barrett's esophagus (BE) is a precancerous change in the epithelial lining of the esophagus that is associated with the development of esophageal cancer. The current best, though imperfect, marker of neoplastic progression is dysplasia (abnormality in cells which have undergone early changes on a path toward possible malignancy) detected in mucosal biopsy specimens of the lining of the esophagus obtained at the time of endoscopy. High-grade dysplasia is associated with a high rate of progression to invasive esophageal cancer. Detection and pathologic confirmation of early BE neoplasia (high-grade dysplasia or early esophageal cancer) is important because endoscopic therapy at this point is highly successful. Unfortunately, neoplasia in BE may not be evident even with only endoscopic inspection, so the current standard of care is endoscopic surveillance with high-quality white-light endoscopy using systematic 4-quadrant biopsies every 1 to 2 cm of BE length and targeted biopsies of any mucosal irregularities. A large number of biopsies may be required using this random biopsy method, resulting in high cost and increased time. This method has a low (1 percent to 10 percent) diagnostic yield for neoplasia and may result in lower adherence to practice guidelines.

Confocal laser endomicroscopy (CLE) is a relatively new endoscopic imaging technique that combines endoscopy and microscopic imaging of the gastrointestinal (GI) mucosa (the superficial lining of the GI tract). A previous single-center, randomized, crossover study, demonstrated a greater diagnostic yield for the detection of BE neoplasia with an in vivo fluorescein-aided endoscope-based CLE system (eCLE).

"Our study compared the diagnostic yield and accuracy of high definition white-light endoscopy (HDWLE) and random biopsy with that of HDWLE plus real-time eCLE imaging and targeted tissue sampling of BE, and determined the impact of in vivo eCLE on real-time clinical decision making in patients with BE," said study lead author Marcia Irene Canto, MD, MHS, FASGE, Johns Hopkins University, Baltimore, Maryland. "We found that real-time eCLE and targeted biopsy after HDWLE can improve the diagnostic yield and accuracy for neoplasia and significantly impact in vivo decision making by altering the diagnosis and guiding therapy."


This was a multicenter, randomized, controlled trial of 192 adult patients with BE undergoing routine surveillance or referred for early neoplasia from February 2010 to December 2012 at academic medical centers. The researchers' objective was to compare high-definition white-light endoscopy (HDWLE) alone with random biopsy (RB) and HDWLE plus eCLE and targeted biopsy (TB) for diagnosis of BE neoplasia. Patients were randomized to HDWLE plus RB (group 1) or HDWLE with eCLE and TB (group 2). Real-time diagnoses and management plans were recorded after HDWLE in both groups and after eCLE in group 2. Blinded expert pathology diagnosis was the reference standard. The main outcomes were diagnostic yield, performance characteristics, and clinical impact.


HDWLE plus eCLE and TB (group 2) led to a lower number of mucosal biopsies and higher diagnostic yield for neoplasia (34 percent vs 7 percent), compared with HDWLE and RB (group 1) but with comparable accuracy. HDWLE plus eCLE and TB tripled the diagnostic yield for neoplasia (22 percent vs 6 percent) and would have obviated the need for any biopsy in 65 percent of patients. The addition of eCLE to HDWLE increased the sensitivity for neoplasia detection to 96 percent from 40 percent without significant reduction in specificity. In vivo CLE changed the treatment plan in 36 percent of patients. An eCLE was performed successfully and safely in all patients. There were no adverse reactions to fluorescein administration.

The researchers noted several limitations including that the study was only at academic centers with highly experienced endoscopists. The results may not be generalizable to community-based physicians, less-experienced practitioners and nonacademic practices. Second, they used the eCLE system, and their findings may not be generalizable to other pCLE systems. Also, the endoscopists were not blinded to prior endoscopy and pathology results because these were necessary for standard medical care and in vivo decision making regarding biopsy or EMR.

The researchers concluded that the addition of in vivo imaging with eCLE to HDWLE is associated with improved targeting of neoplasia, a decrease in unnecessary mucosal biopsies and a significant change in diagnosis and management plans in patients with BE. The approach of real-time CLE diagnosis and imaging-guided therapy represents a potential paradigm shift in BE surveillance. Research studies are needed to address training in CLE, comparative effectiveness studies of advanced endoscopic imaging techniques, the role of imaging-guided therapy and advances in CLE devices and contrast agents.

In an accompanying editorial, Manuel Berzosa, MD and Michael B. Wallace, MD, MPH, Mayo Clinic, Jacksonville, Florida, stated, "This is an important study for Barrett's esophagus surveillance because it demonstrates that a targeted biopsy strategy using endoscope based confocal laser endomicroscopy can be a superior alternative to random biopsy protocols."


Contact: Anne Brownsey
American Society for Gastrointestinal Endoscopy

Related medicine news :

1. Cell therapy shows remarkable ability to eradicate cancer in clinical study
2. Blood pressure medications given right after stroke not beneficial, study finds
3. More women receiving breast reconstruction after mastectomy, study finds
4. Miriam Hospital study shows social gaming site effective weight loss tool
5. Study points out inequalities in prescribing blood pressure meds
6. Blood test serves as crystal ball for heart transplant patients, UCLA-led study finds
7. Study uncovers surprising differences in brain activity of alcohol-dependent women
8. Tinnitus study signals advance in understanding link between loud sounds exposure and hearing loss
9. Pregnancy study leads to fewer high birth weight babies
10. Metal implants may cut chemotherapy side effects, study suggests
11. New study explains how dense breast tissue drives the early stages of cancer
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ compensation ... utilization of hospital and nonhospital care, according to a recent study by the Workers ... 16th Edition , found medical payments per claim with more than seven days of ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo is ... a number even greater among Millennials (a whopping one in three aged 18 to ... people who are dissatisfied with their ink. In fact, RealSelf , the world’s ...
(Date:12/1/2015)... ... 01, 2015 , ... For many X-rays taken at hospitals, ... interpretation by the radiologist. The marking utensils are so small, however, they are ... a way to alleviate this problem. , He developed the patent-pending MARK N ...
(Date:12/1/2015)... ... 01, 2015 , ... Next IT Healthcare, the leader in ... this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the publisher ... in the category of Digital Solutions for its innovative, industry-leading product, Alme Health ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning ... results, once a deal is signed. This quick-read guidance suggests that failing ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Calif. , Dec. 1, 2015 ... products and services, announced today that it has been ... services organization. Members served by Novation will have access ... devices, sports bracing products and soft goods dedicated to ... --> The aging U.S. population, rising prevalence ...
(Date:12/1/2015)... 2015 Russia has always been ... of new drugs registered in Europe in 2015 ... --> Russia has always been a country of ... registered in Europe in 2015 were tested in ... Russia has always been a country of choice for ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology: